(Q46702760)

24 December 2017

title

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients (English)

1 reference

24 December 2017

0 references

7

1 reference

24 December 2017

Willem Weimar

3

object named as

Willem Weimar

1 reference

24 December 2017

Stefan Vítko

1

1 reference

24 December 2017

Raimund Margreiter

2

1 reference

24 December 2017

Jacques Dantal

4

1 reference

24 December 2017

Dirk Kuypers

5

1 reference

24 December 2017

Michael Winkler

6

1 reference

24 December 2017

Hendrik G Viljoen

8

1 reference

24 December 2017

Pavel Filiptsev

9

1 reference

24 December 2017

Sami Sadek

10

1 reference

24 December 2017

Yulan Li

11

1 reference

24 December 2017

Nathalie Cretin

12

1 reference

24 December 2017

Klemens Budde

13

1 reference

24 December 2017

RAD B201 Study Group

14

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

24 December 2017

American Journal of Transplantation

published in

1 reference

24 December 2017

volume

5

1 reference

24 December 2017

issue

10

1 reference

24 December 2017

page(s)

2521-2530

1 reference

24 December 2017

Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

The natural history of chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

The role of Certican (everolimus, rad) in the many pathways of chronic rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Immunosuppression: practice and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Factors associated with long-term renal allograft survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

Sirolimus: a new option in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01063.X

10.1111/J.1600-6143.2005.01063.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16162203

1 reference

24 December 2017